Sequoia Financial Advisors LLC Increases Stock Holdings in Stryker Co. (NYSE:SYK)

Sequoia Financial Advisors LLC lifted its stake in shares of Stryker Co. (NYSE:SYK) by 7.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 12,074 shares of the medical technology company’s stock after buying an additional 838 shares during the period. Sequoia Financial Advisors LLC’s holdings in Stryker were worth $4,347,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of SYK. Parnassus Investments LLC purchased a new position in shares of Stryker during the third quarter valued at approximately $762,798,000. Raymond James Financial Inc. purchased a new position in shares of Stryker during the fourth quarter valued at approximately $353,394,000. Proficio Capital Partners LLC lifted its holdings in Stryker by 52,520.8% during the fourth quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company’s stock worth $214,660,000 after acquiring an additional 595,061 shares during the period. RTW Investments LP bought a new stake in Stryker during the third quarter worth $143,392,000. Finally, State Street Corp lifted its holdings in Stryker by 2.2% during the third quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock worth $5,279,788,000 after acquiring an additional 316,404 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In related news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Price Performance

Shares of NYSE SYK opened at $363.79 on Friday. The stock has a market cap of $138.81 billion, a PE ratio of 46.88, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock has a fifty day moving average of $382.87 and a 200-day moving average of $373.26.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the firm earned $3.46 earnings per share. Equities research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. JPMorgan Chase & Co. lifted their price target on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a report on Thursday, March 6th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. Royal Bank of Canada lifted their price target on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Finally, Citigroup restated a “buy” rating and issued a $450.00 target price on shares of Stryker in a research note on Wednesday, February 26th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average price target of $421.90.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.